RBC Capital analyst Leonid Timashev last night downgraded Bicycle Therapeutics (BCYC) to Sector Perform from Outperform with a price target of $11, down from $27, following the Q3 report. The company’s pipeline programs are taking more time to reach inflection points, the analyst tells investors in a research note. RBC thinks Bicycle’s near-term updates may not provide substantial enough data to de-risk its programs and drive share upside. As such, the firm moves to the sidelines pending greater visibility into the path forward for zelenectide and BT5528.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Bicycle Therapeutics Reports Q3 2025 Financial Results
- Bicycle Therapeutics downgraded to Sector Perform at RBC Capital
- Strategic Regulatory Alignment and Positive Momentum Justify Buy Rating for Bicycle Therapeutics
- Bicycle Therapeutics reports Q3 EPS (85c), consensus ($1.07)
- Bicycle Therapeutics Expands Board with New Appointments